The Boston Globe Names C4 Therapeutics a Top Place to Work for 2017

CAMBRIDGE, Mass. – C4 Therapeutics (C4T) has been named one of the Top Places to Work in Massachusetts in the 10th annual employee-based survey project from The Boston Globe. Top Places to Work recognizes the most admired workplaces in the state voted on by the people who know them best – their employees. The survey measures employee opinions about their…

C4 Therapeutics Appoints Michael Kim as Vice-president of Business Development

CAMBRIDGE, Mass.– C4 Therapeutics (C4T) today announced the appointment of Michael Kim, Ph.D., as Vice President of Business Development. Dr. Kim comes to C4 Therapeutics from ARIAD Pharmaceuticals where he held responsibilities for partnering activities around early and late stage programs in addition to portfolio strategy and alliance management. He started his business career as a strategy…

C4 Therapeutics Announces the Addition of Leading Researchers in Hematology-oncology to Scientific Advisory Board

CAMBRIDGE, Mass. – C4 Therapeutics (C4T) today announced the appointment of Scott Armstrong, M.D, Ph.D., and Ross Levine, MD, to the Company’s Scientific Advisory Board (SAB). “C4T has established a scientific advisory board that brings together leading scientists and physicians representing a range of disciplines,” said Andrew (Andy) Phillips, Ph.D., President and Chief Scientific Officer of C4 Therapeutics…

C4 Therapeutics and Calico Enter Strategic Partnership to Discover Novel Therapeutics Based on Targeted Protein Degradation

CAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif. –  C4 Therapeutics (C4T) and Calico today announced a five-year collaboration to discover, develop and commercialize therapies for treating diseases of aging, including cancer. Under the terms of the agreement, the parties will leverage C4T’s expertise and capabilities in targeted protein degradation to jointly discover and advance small molecule protein degraders as therapeutic agents…